RBC Capital raised the firm’s price target on Biogen to $363 from $351 and keeps an Outperform rating on the shares. The company’s Q3 results saw a “fast start” for Skyclarys, while the long-term opportunity for Leqembi amid easing infrastructure bottleneck remains intact, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB: